BCLC Stage C Adult Hepatocellular Carcinoma

specific

End-stage hepatocellular carcinoma. Patients will receive symptomatic treatment. (HPB (Oxford) 2005; 7(1):35-41)

Centers

Active Trials

—

Cancer Funding

Top Centers for BCLC Stage C Adult Hepatocellular Carcinoma(20)

Ranked by research excellence score (trials · grants · publications). Methodology →

#	Center	Active Trials	Cancer Funding	Score
1	Yale Cancer Center Yale School of MedicineNew Haven, CT NCI Comprehensive	—	—	52.5
2	Herbert Irving Comprehensive Cancer CenterNew York, NY NCI Comprehensive	—	—	52.5
3	The Ohio State University Comprehensive Cancer Center - James Cancer Hospital & Solove Research InstituteColumbus, OH NCI Comprehensive	—	—	52.5
4	City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive	—	—	52.5
5	USC Norris Comprehensive Cancer CenterLos Angeles, CA NCI Comprehensive	—	—	52.5
6	University of Colorado Cancer CenterAurora, CO NCI Comprehensive	—	—	52.5
7	Moffitt Cancer CenterTampa, FL NCI Comprehensive	—	—	52.5
8	Huntsman Cancer Institute at the University of UtahSalt Lake City, UT NCI Comprehensive	—	—	52.5
9	UC Davis Comprehensive Cancer CenterSacramento, CA NCI Comprehensive	—	—	52.5
10	University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive	—	—	52.5
11	Sylvester Comprehensive Cancer CenterMiami, FL NCI Clinical	—	—	52.5
12	The University of Kansas Cancer CenterKansas City, KS NCI Comprehensive	—	—	52.5
13	University of Illinois Cancer CenterChicago, IL	—	—	52.5
14	University of New Mexico Comprehensive Cancer CenterAlbuquerque, NM NCI Comprehensive	—	—	52.5
15	Boston University Cancer CenterBoston, MA	—	—	52.5
16	Karmanos Cancer InstituteDetroit, MI NCI Comprehensive	—	—	52.5
17	Houston Methodist Dr. Mary and Ron Neal Cancer CenterHouston, TX	—	—	52.5
18	Cancer Center at IllinoisUrbana, IL	—	—	52.5
19	University of Cincinnati Cancer CenterCincinnati, OH	—	—	52.5
20	Tampa General Hospital Cancer InstituteTampa, FL	—	—	52.5

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →